Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Authors:
Open Access
- 8 June 2023
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (9) , 2732-2747
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Optimum Patient Care
- AstraZeneca UK Limited
This publication has 44 references indexed in Scilit:
- Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional studynpj Primary Care Respiratory Medicine, 2015
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsThe Lancet Respiratory Medicine, 2015
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma RegistryThorax, 2014
- Defining Phenotypes in Asthma: A Step Towards Personalized MedicineDrugs, 2014
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trialsStatistics in Medicine, 2006
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004